risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients in the U.S. with obesity or overweight and ...

Study: Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data. Image Credit: memorisz / Shutterstock A team of researchers at the University of Bern ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients with obesity or overweight and established ...